Navigation Links
Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
Date:6/17/2009

ible will be treated with Doxil(R) (pegylated liposomal doxorubicin), an approved drug used to treat ovarian cancer, or with EC145, which combines Doxil with folate (vitamin B-9).

The PRECEDENT study is yet another example of CTCA's commitment to expanding medical treatment options for women battling ovarian cancer. In October 2008, CTCA at Midwestern Regional Medical Center announced a ground-breaking clinical trial of an ovarian cancer vaccine called o-Vax that uses cells taken from an individual patient's tumor to stimulate immune cells to attack the existing cancer. Patients continue to be accepted for this clinical trial.

"CTCA offers a powerful combination of traditional and innovative therapies provided by a team of cancer experts who work with each patient individually, to determine the appropriate combination of therapies to fight cancer," Dr. Williams says.

Ovarian cancer is the ninth most common cancer among women, and the leading cause of death due to cancer of the female reproductive system. According to the American Cancer Society, it is estimated that there will be 21,550 new cases of ovarian cancer in the U.S. in 2009 and 14,600 cancer-related deaths. A woman's risk of getting invasive ovarian cancer during her lifetime is about one out of every 71 women.

Patients interested in the clinical trial may contact a CTCA Oncology Information Specialist at 877-98-TRIAL.

About Cancer Treatment Centers of America

Founded in 1988, Cancer Treatment Centers of America (CTCA) provides a comprehensive, patient-centered treatment model that fully integrates traditional, state-of-the-art medical treatments with scientifically-supported complementary and alternative therapies such as nutrition, naturopathy, psychological counseling, physical therapy and spiritual support to meet
'/>"/>

SOURCE Cancer Treatment Centers of America
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
2. Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
3. Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients
4. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
5. Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis
6. Advance in Bowel Cancer Test Research
7. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
8. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
9. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
10. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
11. Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... 21, 2013  Armada Health Care (Armada) is ... Armada corporate website ( www.armadahealthcare.com ).  This new ... and first-to-market services and its position as the ... specialty pharmacy industry. The updated website ... business model in delivering an extensive portfolio of ...
(Date:5/21/2013)... 2013 Hurel Corporation ("Hurel"), a world-leading provider ... platforms, today announced the appointment of James ... Board of Directors. Dr. MacDonald is the former Executive ... Institute ("SPRI"), which was the pharmaceutical development arm of ... Co. in 2009. Over a career that ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2
... 2011 Healthpoint today announced the launch of a ... Biotherapeutics, along with an updated brandmark and corporate tagline, ... is designed to communicate the company,s commitment to scientific ... contribute to improved outcomes and quality of life for ...
... Md., Feb. 23, 2011 The Cystic Fibrosis Foundation and ... development that targets the defective protein that causes cystic fibrosis, ... The trial was designed to evaluate patients age ... a CF mutation called G551D. The study included 161 patients ...
Cached Medicine Technology:Healthpoint Launches New Corporate Identity 2Healthpoint Launches New Corporate Identity 3Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 3
(Date:5/21/2013)... (PRWEB) May 21, 2013 Diversity Focus, ... working environments for all residents in the Creative Corridor ... Community Survey at a news conference on Thursday, May ... benchmark study, conducted in 2008. , The ... to lead and support efforts that attract, nurture and ...
(Date:5/21/2013)... May 21, 2013 MedMar Healing Center ... to benefit Second Harvest Food Bank. Twenty-eight businesses, including MedMar ... in the food drive. The goal is to raise food ... economic problems facing their families in recent years. , ... and help those in need,” explains Douglas Chloupek of MedMar ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
(Date:5/21/2013)... Colo. (May 21, 2013) Research into genetic features ... University of Colorado School of Medicine may lead to ... a paper published online by JAMA . , ... predict survival in some cases of pulmonary fibrosis, a ... years. As a result of the study, researchers may ...
(Date:5/21/2013)... and technological research So Paulo Research Foundation, FAPESP, based ... estimated in US$ 680 million to support 17 Research, ... up to eleven years, subject to continuation reviews on ... the 17 RIDCs will come from FAPESP and the ... infrastructure). Host institutions will participate in a portion of ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2
... 5, 2011 The new edition of America Speaks, ... demonstrates increasing public support for research and innovation to ... nearly 60% of Americans don,t believe we are making ... the U.S. has the best health care system in ...
... -- By gluing together cells from different genomes to form ... chimeric monkeys. In the report published online and ... said the monkeys, who are made up of as many ... successfully implanting these genetically mixed rhesus monkey embryos into mothers, ...
... HealthDay Reporter , THURSDAY, Jan. 5 (HealthDay News) ... annoying and painful but ultimately harmless problem -- a result ... a hangover after a night of drinking. But frequent ... known as gastroesophageal reflux disease, or GERD, and GERD is ...
... More than half of U.S. jails didn,t receive any vaccine ... flu, a new study says. Jail and prison inmates ... steady stream of new arrivals can introduce new types of ... for diseases to spread, researchers from the U.S. Centers for ...
... been linked to depression, according to UT Southwestern Medical ... It is believed to be the largest such investigation ... are associated with a cavalcade of health woes from ... published in Mayo Clinic Proceedings helps ...
... , THURSDAY, Jan. 5 (HealthDay News) -- Toddlers who ... disorders later in life, a new study indicates. Researchers ... found that depriving them of a single daily nap resulted ... reduced problem-solving abilities. "Many young children today are not ...
Cached Medicine News:Health News:Majority of Americans say research and development are key to building US economy 2Health News:Scientists Create First Monkeys With Mixed Genomes 2Health News:Chronic Heartburn a Growing Problem in U.S. 2Health News:Chronic Heartburn a Growing Problem in U.S. 3Health News:Many Jails Got No Flu Shots During H1N1 Outbreak: CDC 2Health News:Low vitamin D levels linked to depression, UT Southwestern psychiatrists report 2Health News:Missed Naps Could Put Toddlers at Risk for Mood Disorders 2
... Synergy T-EP - EMG/EP monitoring systems range ... T2EP, T5EP and T10EP systems. These 2, ... in collaboration with leading practitioners, for ease ... of clinical testing. Synergy T-EP harnesses PC ...
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
... MYOHANDY family are probably the most ... SystemPLUS line. Based on last generation ... the ISA 100x EP series with ... EP) , 4 channels (ISA 1004, ...
Sierra II power & efficiency plus. Sierra II report generator with automatic sentence generation creates the one-minute report. Complete 2/4 channel EMG/NCV/EP....
Medicine Products: